Single arm, phase two study of low-dose metronomic eribulin in metastatic breast cancer.

ABSTRACT:

Background

Treatment options for metastatic breast cancer (MBC) refractory to anthracyclines and taxanes are limited. In a phase III trial, eribulin demonstrated a significant improvement in overall survival compared to treatment of physician's choice, but had limited tolerability because of neutropenia and peripheral neuropathy. Based on prior studies of alternative treatment schedules with other therapies, we hypothesized that a low-dose metronomic schedule of eribulin would permit patients to remain on treatment more consistently without treatment delays, resulting in longer time to progression, and improved toxicity profile.

Methods

We conducted a multi-site single arm, phase II trial patients with MBC. All patients were treated with metronomic eribulin (0.9 mg/m^2</

SUBMITTER: Chalasani P 

PROVIDER: S-EPMC8233258 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature